UK drug update - March 2004
Takeda has introduced a 45mg tablet of Actos containing the oral hypoglycaemic agent pioglitazone.
Almus Pharmaceuticals has launched 2.5, 5, 10 and 20mg tablets of the ACE inhibitor enalapril maleate.
Ferring has marketed Gonapeptyl Depot, containing 3.75mg of the gonadotrophin analogue triptorelin (as acetate).
Genus Pharmaceuticals has made available 2.5mg, 5mg and 10mg capsules of the ACE inhibitor ramipril.
APS/Berk has added the following to its range: 1.25mg, 2.5mg, 5mg and 10mg capsule and tablet formulations of the ACE inhibitor ramipril; and 5mg and 10mg tablets of the loop diuretic torasemide.
Almus Pharmaceuticals has marketed 20mg and 40mg tablets of the loop diuretic frusemide. The company has also added 1mg, 2mg and 4mg tablets of the selective alpha1-blocker doxazosin, and 10mg, 20mg, 40mg and 80mg tablets of the statin simvastatin to its product range.
Sandoz has brought out 1.25mg, 2.5mg, 5mg and 10mg capsules of the ACE inhibitor ramipril.
Schering Health Care has launched Ventaris containing 10µg/mL of the synthetic prostacyclin analogue iloprost.
Allergan Pharmaceuticals has marketed Relestat eye drops containing 0.5mg/mL of the H1 receptor antagonist epinastine hydrochloride (equivalent to 0.436mg epinastine).
IVAX Pharmaceuticals has introduced 1.25mg, 2.5mg, 5mg and 10mg tablets of ramipril.
Abbott Laboratories has introduced Gopten capsules containing 4mg of the ACE inhibitor trandolapril.
Merck Sharp & Dohme has launched Emend containing 80 or 125mg of the antiemetic aprepitant.
Ipsen has introduced Decapeptyl SR, containing 11.25mg of the gonadotrophin releasing hormone analogue triptorelin